Country: United States
Language: English
Source: NLM (National Library of Medicine)
LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987)
SA3, LLC
INTRADERMAL
PRESCRIPTION DRUG
Lidocaine Hydrochloride Monohydrate powder intradermal injection system is indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3–18 years of age. Lidocaine Hydrochloride Monohydrate powder intradermal injection system is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults. Lidocaine Hydrochloride Monohydrate is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. Lidocaine Hydrochloride Monohydrate powder intradermal injection system was not formally evaluated for effects on reproduction. Significant systemic exposure to lidocaine is not expected under recommended conditions of use of Lidocaine Hydrochloride Monohydrate powder intradermal injection system as lidocaine levels were below the limit of detection in human studies. Lidocaine has been previously tested for reproductive toxicity in animal studies, however. The follo
NDC 69420-1230 Lidocaine Hydrochloride Monohydrate powder intradermal injection system contains 0.5 mg of sterile lidocaine hydrochloride monohydrate. Lidocaine HCl Monohydrate injection system is a single-dose device packaged in an individual clear pouch. Twelve pouched devices are placed in labeled cartons. Cartons are stored at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
New Drug Application Authorized Generic
LIDOCAINE HYDROCHLORIDE MONOHYDRATE- LIDOCAINE HYDROCHLORIDE MONOHYDRATE POWDER SA3, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LIDOCAINE HYDROCHLORIDE MONOHYDRATE POWDER INTRADERMAL INJECTION SYSTEM SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LIDOCAINE HYDROCHLORIDE MONOHYDRATE POWDER INTRADERMAL INJECTION SYSTEM. LIDOCAINE HYDROCHLORIDE MONOHYDRATE 0.5MG POWDER INTRADERMAL INJECTION SYSTEM INITIAL U.S. APPROVAL: 1948 RECENT MAJOR CHANGES Warnings and Precautions, Methemoglobinemia (5.1) 12/2018 INDICATIONS AND USAGE • • Important Limitations: • • DOSAGE AND ADMINISTRATION • • • DOSAGE FORMS AND STRENGTHS Lidocaine Hydrochloride Monohydrate powder intradermal injection system is a sterile, single-use, powder intradermal injection system containing 0.5 mg lidocaine hydrochloride monohydrate. (3) Lidocaine Hydrochloride Monohydrate powder intradermal injection system utilizes a helium-powered delivery system. (11) CONTRAINDICATIONS Lidocaine Hydrochloride Monohydrate powder intradermal injection system is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. (4) WARNINGS AND PRECAUTIONS • • • • • ADVERSE REACTIONS The most common adverse reactions (>5%) are skin reactions at the site of administration: erythema, petechiae, edema, and pruritus (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 12/2018 Lidocaine Hydrochloride Monohydrate powder intradermal injection system is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3– 18 years of age. (1) Lidocaine Hydrochloride Monohydrate powder intradermal injection system is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults. (1) For use on intact sk Read the complete document